TABLE 7.
β-Galactosidase activity conferred by ARE1-lacZ and ARE2-lacZ fusions during changes in heme or due to mutations in transcription factors HAP1 and ROX1
| Strain (condition or genotype) | β-Galactosidase activity (fold change relative to wild type)c
|
|
|---|---|---|
| ARE1-lacZ | ARE2-lacZ | |
| TKY22 (50 μg of δ-ALA/ml) | 1.8 ± 0.1 (1.0) | 85 ± 17 (1.0) |
| TKY22 (0.5 μg of δ-ALA/ml) | 9.3 ± 0.2 (5.2) | 9.0 ± 1.5 (0.11) |
| BWG 1-7aa | 1.9 ± 0.2 (1.0) | 155 ± 19 (1.0) |
| LPY22 (hap1) | 1.7 ± 0.3 (0.9) | 25 ± 5.0 (0.16) |
| RZ53-6b | 0.91 ± 0.17 (1.0) | 43 ± 4.7 (1.0) |
| RZ53-6/rox1 | 4.6 ± 0.87 (5.1) | 130 ± 20 (3.0) |
a
The hap1 mutant was created in the BWG 1-7a background.
b
RZ53-6 is the wild-type strain isogenic to the rox1 mutant.
c
β-Galactosidase activity is reported as nanomoles of o-nitrophenyl-β-d-galatopyranoside hydrolyzed per minute per milligram of protein and is the average of two independent transformants assayed in duplicate over 3 days.